Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study.

Published in: Eye (London, England) (2023)

ADA seems to be effective and safe with good DRR to control ocular inflammation. Escalation to weekly ADA treatment may be an effective option in patients with primary or secondary inefficacy.

Keyphrases

oxidative stress
juvenile idiopathic arthritis
rheumatoid arthritis
clinical trial
randomized controlled trial
systemic lupus erythematosus
ankylosing spondylitis
replacement therapy
ulcerative colitis